World Journal of Gastroenterology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

JOURNAL HOME

Number of total visits: 33457635

Number of visits today: 3094

Number of downloads: 16640823

MEMBERSHIP

BPG JOURNALS

Cited by in F6Publishing

For:	Ushida Y, Inoue Y, Oba A, Mie T, Ito H, Ono Y, Sato T, Ozaka M, Sasaki T, Saiura A, Sasahira N, Takahashi Y. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study. Ann Surg Oncol 2022. [PMID: 35294658 DOI: 10.1245/s10434-022-11503-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]

For:

Ushida Y, Inoue Y, Oba A, Mie T, Ito H, Ono Y, Sato T, Ozaka M, Sasaki T, Saiura A, Sasahira N, Takahashi Y. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study. Ann Surg Oncol 2022. [PMID: 35294658 DOI: 10.1245/s10434-022-11503-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]

Number	Citing Articles
1	Jung JH, Song C, Jung IH, Ahn J, Kim B, Jung K, Lee JC, Kim J, Hwang JH. Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer. Front Oncol 2022;12:1050070. [PMID: 36620548 DOI: 10.3389/fonc.2022.1050070] [Reference Citation Analysis]
2	Mie T, Sasaki T, Okamoto T, Takeda T, Mori C, Furukawa T, Kasuga A, Matsuyama M, Ozaka M, Sasahira N. Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer. Jpn J Clin Oncol 2022;52:1399-407. [PMID: 36111430 DOI: 10.1093/jjco/hyac145] [Reference Citation Analysis]
3	Ushida Y, Inoue Y, Oba A, Mie T, Ito H, Ono Y, Sato T, Ozaka M, Sasaki T, Saiura A, Sasahira N, Takahashi Y. ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy? Ann Surg Oncol. [DOI: 10.1245/s10434-022-11621-1] [Reference Citation Analysis]